Patient Selection For Oxervate
Wondering who might be a good candidate for treatment with the biologic Oxervate (cenegermin-bkbj)? W. Barry Lee, MD, FACS, and Clifford Salinger, MD, talk about the different classifications of neurotrophic keratitis and how they choose or identify patients who they believe will benefit from the drug.
Breakthrough Therapy for Neurotrophic Keratitis
Marjan Farid, MD; Christopher J. Rapuano, MD; Kenneth A. Beckman, MD; Francis S. Mah, MD; and Marguerite B. McDonald, MD, share their experiences diagnosing and treating neurotrophic keratitis (NK) with Oxervate (cenegermin-bkbj). The physicians discuss common etiologies that lead to NK, what leads them to suspect the disease, and how Oxervate fits within current treatment options.Read Supplement »
Kenneth A. Beckman, MD
Marjan Farid, MD
Francis S. Mah, MD